Skip to main content

30-06-2019 | Multiple sclerosis | Video

EAN 2019: Reductions in 48-week confirmed MS disability progression sustained with ocrelizumab

Gavin Giovannoni provides his thoughts on ocrelizumab’s sustained effect on disability progression risk reduction in multiple sclerosis patients based on a 5-year follow-up of pooled data from the OPERA I and II trials (4:19).

Funding for independent interviews at EAN 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits